A new treatment for pancreatic cancer using targeted drug delivery
An Aptamer-directed IgG1-Fc Drug Conjugate (AFDC) for Treating Pancreatic Cancer
['FUNDING_SBIR_1'] · ONCOTRAP, INC. · NIH-10761053
This study is testing a new treatment designed to target pancreatic cancer cells more effectively while sparing healthy cells, aiming to improve outcomes for patients battling this tough disease.
Quick facts
| Phase | ['FUNDING_SBIR_1'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ONCOTRAP, INC. (nih funded) |
| Locations | 1 site (CHAPEL HILL, UNITED STATES) |
| Trial ID | NIH-10761053 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel treatment for pancreatic ductal adenocarcinoma (PDAC), a type of cancer known for its poor prognosis. The approach involves creating an Aptamer-directed IgG1-Fc Drug Conjugate (AFDC) that specifically targets PDAC cells while minimizing effects on normal cells. By combining a unique aptamer that binds to cancer cells with a drug delivery system, the research aims to enhance the effectiveness of treatment and improve patient outcomes. The project will validate the ability of this new treatment to kill PDAC cells and optimize its formulation for clinical use.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who have limited treatment options.
Not a fit: Patients with other types of cancer or those who do not have pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment option for patients with pancreatic cancer, potentially improving survival rates.
How similar studies have performed: While antibody-drug conjugates have shown success in treating other cancers, this specific approach for pancreatic cancer is novel and has not been extensively tested.
Where this research is happening
CHAPEL HILL, UNITED STATES
- ONCOTRAP, INC. — CHAPEL HILL, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GAO, XIANG — ONCOTRAP, INC.
- Study coordinator: GAO, XIANG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers